A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS)
Anti-CD20 Therapy

Interventions

DRUG: Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)
DRUG: Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)

Sponsor

University Hospital, Montpellier